{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:47:35Z","timestamp":1793659655389,"version":"4.5.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Grant Y-Young2022\u20140225"],"award-info":[{"award-number":["Grant Y-Young2022\u20140225"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59865-1","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T16:11:19Z","timestamp":1747498279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4043-3196","authenticated-orcid":false,"given":"Zhigang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingpeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjuan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaodan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhutian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-633X","authenticated-orcid":false,"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"59865_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3322\/caac.21384","volume":"67","author":"KD Shield","year":"2017","unstructured":"Shield, K. D. et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J. Clin. 67, 51\u201364 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"59865_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fonc.2018.00563","volume":"8","author":"B Yang","year":"2018","unstructured":"Yang, B. et al. Progresses and perspectives of anti-PD-1\/PD-L1 antibody therapy in head and neck cancers. Front Oncol. 8, 563 (2018).","journal-title":"Front Oncol."},{"key":"59865_CR3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med"},{"key":"59865_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"59865_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"59865_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","volume":"52","author":"B Solomon","year":"2018","unstructured":"Solomon, B., Young, R. J. & Rischin, D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin. cancer Biol. 52, 228\u2013240 (2018).","journal-title":"Semin. cancer Biol."},{"key":"59865_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89829","volume":"1","author":"R Mandal","year":"2016","unstructured":"Mandal, R. et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI insight 1, e89829 (2016).","journal-title":"JCI insight"},{"key":"59865_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","volume":"4","author":"L Galluzzi","year":"2016","unstructured":"Galluzzi, L., Zitvogel, L. & Kroemer, G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol. Res. 4, 895\u2013902 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"59865_CR9","doi-asserted-by":"crossref","unstructured":"Topalian, S. L., Taube J. M. & Pardoll D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).","DOI":"10.1126\/science.aax0182"},{"key":"59865_CR10","doi-asserted-by":"crossref","unstructured":"Hecht, M. et al. Safety and efficacy of single cycle induction treatment with cisplatin\/docetaxel\/ durvalumab\/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. J. Immunother. Cancer 8, e00137 (2020).","DOI":"10.1136\/jitc-2020-001378"},{"key":"59865_CR11","doi-asserted-by":"crossref","unstructured":"Huang, X. et al. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): an open label, single-arm, phase Ib clinical trial. J. Exp. Clin. Cancer Res. 41, 300 (2022).","DOI":"10.1186\/s13046-022-02510-2"},{"key":"59865_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper, T. M. et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 28, 1345\u20131352 (2022).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"59865_CR13","doi-asserted-by":"crossref","unstructured":"Klochikhin, A. et al. Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689. Clin. Cancer Res. 29, PO-002 (2023).","DOI":"10.1158\/1557-3265.AACRAHNS23-PO-002"},{"key":"59865_CR14","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri, R. et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin. Cancer Res 26, 5140\u20135152 (2020).","journal-title":"Clin. Cancer Res"},{"key":"59865_CR15","doi-asserted-by":"crossref","unstructured":"Zinner R, et al. Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer. 38, 6583\u20136583 (2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.6583"},{"key":"59865_CR16","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","volume":"28","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 28, 3268\u20133276 (2022).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"59865_CR17","first-page":"2220","volume":"109","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial). Int. J. Surg. (Lond., Engl.) 109, 2220\u20132227 (2023).","journal-title":"Int. J. Surg. (Lond., Engl.)"},{"key":"59865_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70206","volume":"13","author":"Q Tang","year":"2024","unstructured":"Tang, Q. et al. Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: a prospective, single-arm, exploratory phase II trial. Cancer Med. 13, e70206 (2024).","journal-title":"Cancer Med."},{"key":"59865_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108\u2013133 (2022).","journal-title":"Cancer Discov."},{"key":"59865_CR20","doi-asserted-by":"crossref","unstructured":"Barsoumian, H.B. et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J. Immunother. Cancer 8, e000537 (2020).","DOI":"10.1136\/jitc-2020-000537"},{"key":"59865_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"59865_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014).","journal-title":"Immunity"},{"key":"59865_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Investig. 124, 687\u2013695 (2014).","journal-title":"J. Clin. Investig."},{"key":"59865_CR24","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 11, 728\u2013734 (2005).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"59865_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ygyno.2010.10.018","volume":"120","author":"CA Kunos","year":"2011","unstructured":"Kunos, C. A. et al. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the gynecologic oncology group. Gynecologic Oncol. 120, 224\u2013228 (2011).","journal-title":"Gynecologic Oncol."},{"key":"59865_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ijrobp.2020.09.059","volume":"109","author":"NYL Ngoi","year":"2021","unstructured":"Ngoi, N. Y. L. et al. Phase 1 study of low-dose fractionated whole abdominal radiation therapy in combination with weekly paclitaxel for platinum-resistant ovarian cancer (GCGS-01). Int. J. Radiat. Oncol., Biol., Phys. 109, 701\u2013711 (2021).","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"key":"59865_CR27","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.ijrobp.2003.09.019","volume":"58","author":"SM Arnold","year":"2004","unstructured":"Arnold, S. M. et al. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int. J. Radiat. Oncol., Biol., Phys. 58, 1411\u20131417 (2004).","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"key":"59865_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13566-012-0074-3","volume":"2","author":"JF Gleason Jr.","year":"2013","unstructured":"Gleason, J. F. Jr. et al. Low-dose fractionated radiation with induction chemotherapy for locally advanced head and neck cancer: 5 year results of a prospective phase II trial. J. Radiat. Oncol. 2, 35\u201342 (2013).","journal-title":"J. Radiat. Oncol."},{"key":"59865_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.adro.2016.06.003","volume":"1","author":"SM Arnold","year":"2016","unstructured":"Arnold, S. M. et al. Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: results of a prospective phase 2 trial. Adv. Radiat. Oncol. 1, 252\u2013259 (2016).","journal-title":"Adv. Radiat. Oncol."},{"key":"59865_CR30","doi-asserted-by":"crossref","unstructured":"Leidner, R. et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J. Immunother. Cancer 9, e002485 (2021).","DOI":"10.1136\/jitc-2021-002485"},{"key":"59865_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1334408","volume":"14","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma. Front. Immunol. 14, 1334408 (2023).","journal-title":"Front. Immunol."},{"key":"59865_CR32","volume":"11","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ macrophages in immune checkpoint inhibitor therapy. Adv. Sci. (Weinh., Baden.-Wurtt., Ger.) 11, e2401061 (2024).","journal-title":"Adv. Sci. (Weinh., Baden.-Wurtt., Ger.)"},{"key":"59865_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","volume":"623","author":"N Caronni","year":"2023","unstructured":"Caronni, N. et al. IL-1\u03b2(+) macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415\u2013422 (2023).","journal-title":"Nature"},{"key":"59865_CR34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","volume":"185","author":"R Nalio Ramos","year":"2022","unstructured":"Nalio Ramos, R. et al. Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer. Cell 185, 1189\u20131207.e1125 (2022).","journal-title":"Cell"},{"key":"59865_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2025.02.010","volume":"43","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer cell 43, 361\u2013379.e310 (2025).","journal-title":"Cancer cell"},{"key":"59865_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","volume":"7","author":"A Pataer","year":"2012","unstructured":"Pataer, A. et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J. Thorac. Oncol. 7, 825\u2013832 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"59865_CR37","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1200\/JCO.2012.43.8820","volume":"31","author":"LP Zhong","year":"2013","unstructured":"Zhong, L. P. et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J. Clin. Oncol. 31, 744\u2013751 (2013).","journal-title":"J. Clin. Oncol."},{"key":"59865_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46444-z","volume":"15","author":"D Wu","year":"2024","unstructured":"Wu, D. et al. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nat. Commun. 15, 2177 (2024).","journal-title":"Nat. Commun."},{"key":"59865_CR39","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto, R. et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 27, 4557\u20134565 (2021).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"59865_CR40","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"MD Hellmann","year":"2014","unstructured":"Hellmann, M. D. et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 15, e42\u201350 (2014).","journal-title":"Lancet Oncol."},{"key":"59865_CR41","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","volume":"22","author":"NK Altorki","year":"2021","unstructured":"Altorki, N. K. et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 22, 824\u2013835 (2021).","journal-title":"Lancet Oncol."},{"key":"59865_CR42","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10637-022-01293-9","volume":"40","author":"P Shen","year":"2022","unstructured":"Shen, P., Qiao, B., Jin, N. & Wang, S. Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. Invest N. Drugs 40, 1282\u20131289 (2022).","journal-title":"Invest N. Drugs"},{"key":"59865_CR43","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s43018-022-00450-6","volume":"3","author":"LB Darragh","year":"2022","unstructured":"Darragh, L. B. et al. A phase I\/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat. cancer 3, 1300\u20131317 (2022).","journal-title":"Nat. cancer"},{"key":"59865_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43462-1","volume":"14","author":"S Li","year":"2023","unstructured":"Li, S. et al. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells. Nat. Commun. 14, 7709 (2023).","journal-title":"Nat. Commun."},{"key":"59865_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166789","volume":"1869","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Exploring low-dose radiotherapy to overcome radio-immunotherapy resistance. Biochimica et. Biophysica Acta Mol. basis Dis. 1869, 166789 (2023).","journal-title":"Biochimica et. Biophysica Acta Mol. basis Dis."},{"key":"59865_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos, J. L. et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat. Commun. 12, 7348 (2021).","journal-title":"Nat. Commun."},{"key":"59865_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3892\/or.2020.7890","volume":"45","author":"Z Guo","year":"2021","unstructured":"Guo, Z. et al. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2. Oncol. Rep. 45, 523\u2013534 (2021).","journal-title":"Oncol. Rep."},{"key":"59865_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2020.09.022","volume":"498","author":"C Ni","year":"2021","unstructured":"Ni, C. et al. ACOT4 accumulation via AKT-mediated phosphorylation promotes pancreatic tumourigenesis. Cancer Lett. 498, 19\u201330 (2021).","journal-title":"Cancer Lett."},{"key":"59865_CR49","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"59865_CR50","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59865-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59865-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59865-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T17:01:57Z","timestamp":1747501317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59865-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59865"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59865-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4608"}}